NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has entered into a definitive purchase agreement for the sale of 12,500,000 shares of its common stock and corresponding warrants to purchase 12,500,000 shares of its common stock to certain investors in a private placement
EDEN PRAIRIE, Minn., Jan. 12, 2021 /PRNewswire/ -- NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announced today that it has entered into a definitive purchase agreement for the sale of 12,500,000 shares of its common stock and corresponding warrants to purchase 12,500,000 shares of its common stock to certain investors in a private placement. Each share of common stock and corresponding warrant is being sold at an aggregate purchase price of $1.00 for anticipated gross proceeds of $12,500,000. The proposed offering is anticipated to close on or about January 14, 2021, subject to the satisfaction of customary closing conditions. Proceeds from the proposed offering are expected to be used for general corporate and working capital purposes. Kestrel Merchant Partners LLC is acting as the exclusive sponsor and The Benchmark Company, LLC is acting as the sole placement agent for the proposed offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. The securities to be sold in the proposed offering have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the U.S. Securities and Exchange Commission (the “SEC”) or an applicable exemption from such registration requirements. NeuroOne has agreed to file a registration statement with the SEC registering the resale of the shares of its common stock and the warrants sold in the proposed offering, as well as the shares of its common stock issuable upon exercise of such warrants. About NeuroOne Forward Looking Statements
SOURCE NeuroOne Medical Technologies Corporation | ||
Company Codes: OTC-PINK:NMTC, OTC-QB:NMTC |